Leuprorelina Acetate 22.5mg/pfs
| Product Overview | |
| Generic Name | Leuprorelina Acetate 22.5mg/pfs |
| Brand Name(s) | ELIGARD |
| Product Type | Generic |
| Form | PFS |
| Strength | 22.5mg |
| Manufacturing & Regulatory | |
| Country | Canada, USA, India |
| COFEPRIS | 010.000.5450.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | 2–8 °C, protect from light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| CTD Summary | Public CTD-derived summaries via EMA EPAR/SmPC |
Description
This (leuprorelina/leuprolide acetate) is indicated for the treatment of advanced prostate cancer.
It is a long-acting hormonal injection that:
- Suppresses testosterone production
- Slows the growth of testosterone-dependent prostate cancer
- Helps control symptoms and disease progression
The 22.5 mg presentation is administered by subcutaneous injection once every three months. It is a hormonal or androgen-deprivation treatment, not chemotherapy
